In the field of positive day clear endocrinology to add new Ding Shagritin tablets (Bessin) was approved for listing.

Guide: Shagritin is an efficient dipeptide-based peptide enzyme-4 (DPP-4) inhibitor that regulates blood sugar by selectively suppressing DPP-4, raising endogenetic glucoglycline-like peptide-1 (GLP-1) and glucose-dependent insulin-releasing polypeptide (GIP) levels to regulate blood sugar for the treatment of type 2 diabetes in adults.
. Recently, the field of positive day clear endocrinology to add new ding, shagritin tablets (Benin) was approved by the State Drug Administration for listing, and as the same through the consistent evaluation, for the second imitation of the variety, approved adaptive disorders for type 2 diabetes.
with the launch of Shagritin, the product line in the field of endocrinology is becoming more abundant.
Shagritin is an efficient dipeptide peptide enzyme-4 (DPP-4) inhibitor that regulates blood sugar by selectively suppressing DPP-4, raising endogenetic glucoglycline-like peptide-1 (GLP-1) and glucose-dependent insulin-releasing polypeptide (GIP) levels for the treatment of type 2 diabetes in adults.
compared with traditional sugar-lowering drugs, DPP-4 inhibitors have the characteristics of not increasing the risk of hypoglycemia, neutral effect on weight and good cardiovascular safety, and have become one of the main treatment options for oral drug treatment for type 2 diabetes.
2017, the product was included in the National Health Insurance Directory (Category B).
is a global disease, China's diabetes accounted for 1/3 of the total number of diabetes, of which type 2 diabetes accounted for more than 90%.
if diabetes is not adequately controlled, it can also cause some acute complications.
, DPP-4 inhibitors have important clinical value for people with type 2 diabetes with large base and increasing incidence.
is sunny Benin and the original drug dosage form consistent, the type of raw materials consistent, the specification is 5mg.
after pharmaceutical and clinical BE trial research, is day-clear homemade preparations and compared preparations in the body biological equivalent.
the product has significant advantages in terms of safety, quality control and so on, clinical positioning is clear, widely used, can give patients more economical choice of drug use.
In recent years, Zhengdaqing to the country's basic medical needs and unseeded clinical needs of the supply of drugs as the direction, relying on excellent research and development capabilities and strong production capacity, focusing on building tumors, liver disease, respiratory diseases, infection, endocrine, cardiovascular six product clusters.
endocrine field, in the field of diabetes, in addition to the listed products such as saglitatin, metformin hydrochloride slow release tablets, Zhengda Qing has more than 10 products under study, including a number of innovative drugs and insulin.
.